nr2a

QNZ46 是一种 NR2C NR2D 选择性 NMDA 受体非竞争性拮抗剂。

Ifenprodil tartrate 是典型的非竞争性 NMDA 受体拮抗剂，抑制 GIRK (Kir3)，通过基底 GIRK 活性减少内向电流，有用做脑血管舒张试剂的潜力。它对 NR1A NR2B 受体亲和力是 NR1A NR2A 受体的 400 倍。

Ro 25-6981 是一种有效的选择性活性依赖性 NMDA 受体阻滞剂，含有 NR2B 亚基，对克隆受体亚基组合 NR1C NR2B 和 NR1C NR2A 的 IC50 分别为 0.009 和 52 μM。 Ro 25-6981 可用于帕金森病的研究。

Eliprodil (SL-820715) 是NR2B-NMDA 受体高效选择性抑制剂，IC50值1uM。它对NR2A-和NR2C-NMDA 受体作用较弱，可用于研究帕金森病和运动障碍治疗的试验。

TCN 213 是一种可克服的(surmountable)、甘氨酸依赖的 GluN1 GluN2A NMDAR 选择性拮抗剂，当甘氨酸的含量为75、 750、7500 nM 时，IC50s 值分别为 0.55、3.5、40 μM。它可用于在药理学上监测 NMDAR 表达在发育中的皮层神经元中的转换。

Ro 25-6981 Maleate 是一种具有选择性的 NR2B 亚基特异性 NMDA 受体 拮抗剂，具有抗惊厥抗抑郁活性，可用于研究帕金森和癫痫等神经系统疾病。

Tat-NR2B9c acetate (NA-1 acetate) 是一种突触后密度 95 (PSD-95) 抑制剂，对 PSD-95d2 (PSD-95 PDZ domain 2) 和 PSD-95d1 的 EC50 值分别为 6.7 nM 和 670 nM。它破坏 PSD-95 NMDAR 相互作用，抑制 NR2A 和 NR2B 与 PSD-95 的结合，IC50 值分别为 0.5 μM 和 8 μM。它还抑制神经元一氧化氮合酶 (nNOS) PSD-95 相互作用，并具有神经保护功效。

Tat-NR2BAA is an inactive control peptide of Tat-NR2B9c. It shares a similar sequence with Tat-NR2B9c, but possesses a double-point mutation in the COOH terminal tSXV motif. This mutation renders Tat-NR2BAA unable to bind PSD-95. Tat-NR2B9c, on the other hand, is a membrane-permeable peptide that interferes with PSD-95 NMDAR binding. This interference leads to the decoupling of NR2B- and or NR2A-type NMDARs from PSD-95[1][2].

N-Methyl-D-aspartate (NMDA) receptors are Ca2+ permeable ligand-gated channels of the central nervous system that are activated after binding of the co-agonists glutamate and glycine. CAY10608 is a propanolamine that potently, selectively, and non-competitively antagonizes the NR2B subunit of NMDA receptors (IC50 = 50 nM). It does not inhibit NR1, NR2A, NR2C, and NR2D subunits and has no significant effects on α-amino-3-hydroxy-5-methyl-4-isoxazolepropioinic acid (AMPA) or kainate receptors. CAY10608 is neuroprotective, since it prevents NMDA-triggered release of lactate dehydrogenase from cultured cortical neurons. Also, CAY10608, when administered intraperitoneally, reduces brain infarct volume resulting from transient ischemia via carotid artery occlusion.

PEAQX (NVP-AAM077) 是 NR2A 高效选择性 NMDA 受体拮抗剂，IC50值为270nM。

Tat-NR2BAA TFA 是 Tat-NR2B9c 的对照肽 (control peptide)，没有活性。Tat-NR2BAA TFA 的序列与 Tat-NR2B9c 相似，但在 COOH 末端 tSXV 基序中有一个双点突变，这使得它无法结合 PSD-95。Tat-NR2B9c TFA 是一种可通透细胞膜的多肽，破坏 PSD-95 NMDAR 的结合。

TCN 201 是选择性的、有效的，非竞争性的GluN1 GluN2A NMDA 受体拮抗剂，pIC50值为 6.8。与 GluN1 GluN2B NMDA 受体 (pIC50<4.3) 相比，它对 GluN1 GluN2A NMDA 受体具有选择性。

Dityrosine, an oxidation product of protein formed through the intermolecular cross-linking of tyrosyl radicals from the reactive oxygen species (ROS) and tyrosine interaction, is associated with decreased hippocampal expression of NMDA receptor subunits Nr1, Nr2a, and Nr2b when administered intragastrically at 320 µg kg per day, leading to memory impairments in mice as evidenced by their performance in a novel object recognition test. Additionally, it raises fasting blood glucose levels while reducing plasma insulin levels and the pancreatic expression of insulin synthesis-related genes Ins2, Pdx1, and MafA. Increased dityrosine levels have been positively linked to a range of diseases, including autism spectrum disorder, cataracts, Alzheimer’s disease, Parkinson’s disease, atherosclerosis, and cystic fibrosis.

GluN2B (formally NR2B) selective, competitive antagonist of the NMDA receptor. Blocks NMDA-evoked current in mouse cortical neurons (IC50 = 480 nM); also inhibits NMDA-evoked responses in oocytes expressing GluN2B (formally NR2B), but not GluN2A (formally